Galderma’s Q3 2026 Results: Neuromodulators Surge 24% as Filler Demand Cools
Galderma’s third-quarter numbers show neuromodulators up 24.1% and fillers up 4.8%, with Sculptra still growing at double digits. Here is what the split says about how patients are choosing treatments, and why part of the jump is an accounting rebound.
Galderma’s Q3 2026 Results: Neuromodulators Surge 24% as Filler Demand Cools Read More »
